RAPGEF5 and COVID-19: Also increased urea, enzymes (AST, CK), D-dimers, procalcitonin, ferritin, and IL-6; and decreased GFR, albumin, lymphocytes, and platelets are markers with unfavorable prognosis for COVID-19 in T2D patients during the treatment period.